FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Wilkinson Peter J 2. Issuer Name and Ticker or Trading Symbol LABORATORY CORP OF AMERICA HOLDINGS [ LH ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
SVP, Chief Accounting Officer
(Last)         (First)         (Middle)
231 MAPLE AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)
2/12/2021
(Street)
BURLINGTON, NC 27215
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  2/12/2021    M    187  A  (1) 710.2194  D   
Common Stock  2/12/2021    F(2)    62  D $238.26  648.2194  D   
Common Stock  2/12/2021    M    680  A  (1) 1328.2194  D   
Common Stock  2/12/2021    F(2)    201  D $238.26  1127.2194  D   
Common Stock  2/18/2021    M    1533  A $146.59  2660.2194  D   
Common Stock  2/18/2021    S    2317  D $241.5146 (3) 343.2194  D   
Common Stock  2/18/2021    M    633  A $182.51  976.2194  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit   (1) 2/12/2021    M        187    (4)  (4) Common Stock  187  $0  2347 (5) D   
Restricted Stock Unit   (1) 2/12/2021    M        680    (4)  (4) Common Stock  680  $0  1667 (5) D   
Non-qualified Stock Options (6) $146.59  2/18/2021    M        1533   2/12/2020 (7) 2/11/2029  Common Stock  1533  $0  767  D   
Non-qualified Stock Options (6) $182.51  2/18/2021    M        633   2/4/2021 (7) 2/3/2030  Common Stock  633  $0  1267  D   

Explanation of Responses:
(1)  Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
(2)  Stock withholding to satisfy tax withholding obligations.
(3)  The price of $241.5146 per share represents a weighted average of sales prices ranging from $240.92 to $241.651 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
(4)  The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020.
(5)  This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
(6)  Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
(7)  The option vests in three equal annual installments beginning on the date reflected in this column.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Wilkinson Peter J
231 MAPLE AVENUE
BURLINGTON, NC 27215


SVP, Chief Accounting Officer

Signatures
/s/ Sandra D. van der Vaart, Attorney-in-Fact for Peter J. Wilkinson 2/19/2021
**Signature of Reporting Person Date